The slip
PARKINSON RECEIPTno. 10850
26 Oct 2026, 12:45 UTCdopamine neurons, braak
predictionRAPGEF3 in dopamine neurons tracks Braak Lewy-body stage
registered9a2961b5dd2b3b70
discovery-0.45 p=0.227 n=9
replication+0.22 p=0.570 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.45, p 0.227)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTfd40813f45ad5b5fd21d33df…
follows c5a39e6a76e8…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 10850: RAPGEF3 in dopamine neurons, braak
- power
- full sample -0.19 (p 0.444, n 18), 95% CI -0.60 to +0.30. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.671, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.671, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.11, sign flips 0; without severely affected donors -0.19 (p 0.444, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.67 (p 0.0022, n 18) vs -0.19 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAPGEF3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RAPGEF3 · oligodendrocytes · braak: substantia nigra, an independent cohort (already registered)